MedWatch

The Lundbeck Foundation delivers record-breaking result

The Lundbeck Foundation, which is the majority stakeholder in pharmaceutical firm Lundbeck, has had its best year to date, ending 2021 with a profit of DKK 6.9bn (USD 1bn).

Photo: Gregers Tycho/ERH

The very affluent majority owner of pharmaceutical firm Lundbeck, the Lundbeck Foundation, has just announced a historically good year, according to the foundation’s annual report for 2021.

”2021 has been an exceptionally good year for the Lundbeck Foundation. I am very proud of the results that have required a great deal of effort from our employees and subsidiaries. We are therefore well-equipped for a 2022 that looks set to be a challenging year, not least because of the war in Ukraine,” says Lene Skole, CEO of the Lundbeck Foundation, in the press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs